Latest Breaking News On - University of paris france - Page 1 : comparemela.com

(1) Ermium Therapeutics SAS, a research-stage biotechnology company developing innovative therapies for auto-immune diseases is announcing today the expansion of the Company executive management team with the appointment of Dr Annegret Van der Aa as Chief Scientific Officer (CSO) and Chief Development Officer (CDO). Dr Van der Aa brings strong expertise in R&D of drug candidates for auto-immune diseases. Since October 1 rst, 2020, Annegret has been intensely active and has allowed the R&D operations to move on efficiently towards the next R&D milestones along with the selection of clinical indications to be targeted by Ermium Therapeutics compounds. We are very pleased to officially welcome Annegret to Ermium Therapeutics in her new role of CSO/CDO , commented Joël Crouzet, CEO of Ermium Therapeutics. We look forward to working with Annegret to develop Ermium Therapeutics strategy and move forwards our innovative approach for auto-immune diseases .

France generalNordrhein westfalenJean philippe herbeuvalKostenloser wertpapierhandelUniversity of paris franceFrench ministry of researchUniversity of parisHasselt universityErmium therapeuticsChief scientific officerChief development officerErmium therapeuticKurma partnersDomain therapeuticsFrench ministryExecutive officer